ActoBio Therapeutics™ CEO Pieter Rottiers Was Interviewed by SynBioBeta on the Potential of the Innovative ActoBiotics® Platform to Cure Diseases.

ActoBio Therapeutics™ Will Take Part in the 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019 (26th – 28th March) in Boston.

Chief Executive Officer Pieter Rottiers has been invited to participate in a panel discussion entitled “Evaluation of Combination Therapies to Address Unmet Clinical Needs” on Thursday 28th March at 16:30. For more information please visit www.as-immunetolerance.com

ActoBio Therapeutics™ to Present at Biotech Showcase 2019 - Chief Executive Officer Pieter Rottiers will present an overview of the innovative ActoBiotics® platform and its applications on 8th January 2019 in San Francisco.

PR_20181219 Biotech Showcase.pdf

ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes

T1DActoBio.pdf

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib-IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes.pdf

Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund

Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund.pdf

Living Biofactories in Your Prescription Bottle

I'm interested in...

COMPANY NEWS

SCIENTIFIC PUBLICATIONS ONLY

PRESS RELEASES ONLY

OTHER INQUIRY

PRESS - I AM A JOURNALIST (PLEASE SPECIFY YOUR PUBLISHER
)

I have read and agree to the Privacy Policy

Disclaimer for website visitors from the European Economic Area: By submitting your personal data through this contact form, you acknowledge having read and understood our Privacy Policy, which you can find here. By requesting us to contact you via this contact form, you expressly agree to such transfer. If you do not want your personal data to be sent via this website, please do not use this contact form but contact our European office at the following e-mail addresses: ABT.info@actobio.com.

Disclaimer: Any communication or other material that you send to us through the internet or by electronic mail or otherwise, such as any questions, comments, suggestions, investment opportunities, inventions or the like, is and will be deemed to be non - confidential.ActoBio Therapeutics(INTREXON ACTOBIOTICS NV) shall have no obligation of any kind with respect to such information. ActoBio Therapeutics(INTREXON ACTOBIOTICS NV) shall be free to use, anywhere in the world, any ideas, concepts, know - how or techniques contained in such communication for any purpose whatsoever, including but not limited to, public and/or third party disclosure, development, manufacture, marketing, and sales.

If you have any further questions about the way in which we treat your personal data please contact us directly via email to: ABT.info@actobio.com.